Life Science REIT plc
LABS.L
London Stock Exchange- -
GBp
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Simon Mark Farnsworth
- Sector
- Real Estate
- Industry
- REIT - Industrial
- Address
- Beaufort House Exeter United Kingdom EX4 4EP
- IPO Date
- Nov 19, 2021
- Website
- lifesciencereit.co.uk
- Similar Companies
- Business
- Life Science REIT plc (Ticker: LABS.L) is a real estate investment trust focused on owning and managing life sciences properties, including laboratory, research and development, and biomanufacturing facilities. The company offers property leasing services; asset management; and development opportunities for single-use and multi-tenant life sciences real estate, primarily targeting biotech, pharmaceutical, and medical research tenants. Its portfolio includes properties such as the Cambridge Biomedical Campus and facilities in Oxford and London in the United Kingdom, with operations centered in the UK. Founded in 2015 and headquartered in London, England, Life Science REIT plc operates within the healthcare real estate sector, serving academic institutions, contract research organizations, and innovative life sciences companies. The company emphasizes high-quality, strategically located assets in key UK biotech clusters to support tenant growth and scientific advancement. It maintains a diversified tenant base with long-term leases to minimize vacancy risks. In recent developments, Life Science REIT completed the acquisition of a portfolio of life sciences properties from Urbanest in 2024, expanding its asset base and enhancing geographic diversification. The company also secured a significant debt refinancing in late 2024, improving its capital structure and liquidity for future investments. Additionally, it announced new lease agreements with major biotech firms in 2025, bolstering occupancy rates amid ongoing portfolio optimization efforts.